PharmacoEconomics Article Highlights Rare Disease Therapeutics Tied to Patient Outcomes

A recent publication considers how treatments for rare diseases are priced according to patient outcomes. The study aims to compare case studies in different parts of the world to inform healthcare policy.

“Outcomes-based managed entry agreements represent one method of potentially mitigating the impacts of uncertainties in the clinical evidence base, for example, relating to the long-term clinical effectiveness of innovative therapies, at the time of their pricing/reimbursement and market entry.” Read more here.

(Source: The Evidence Base, 7/7/21)